skip to main content
Idioma:

Ceftazidime–avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae

Lima, O. ; Sousa, A. ; Longueira-Suárez, R. ; Filgueira, A. ; Taboada-Martínez, C. ; Portela-Pino, C. ; Nodar, A. ; Vasallo-Vidal, F. ; Martinez-Lamas, L. ; Pérez-Landeiro, A. ; Rubianes, M. ; Pérez-Rodríguez, MT

European journal of clinical microbiology & infectious diseases, 2022-09, Vol.41 (9), p.1173-1182 [Periódico revisado por pares]

Berlin/Heidelberg: Springer Berlin Heidelberg

Texto completo disponível

Citações Citado por
  • Título:
    Ceftazidime–avibactam treatment in bacteremia caused by OXA-48 carbapenemase-producing Klebsiella pneumoniae
  • Autor: Lima, O. ; Sousa, A. ; Longueira-Suárez, R. ; Filgueira, A. ; Taboada-Martínez, C. ; Portela-Pino, C. ; Nodar, A. ; Vasallo-Vidal, F. ; Martinez-Lamas, L. ; Pérez-Landeiro, A. ; Rubianes, M. ; Pérez-Rodríguez, MT
  • Assuntos: Antibiotics ; Bacteremia ; Biomedical and Life Sciences ; Biomedicine ; Carbapenemase ; Ceftazidime ; Epidemiology ; Internal Medicine ; Klebsiella ; Klebsiella pneumoniae ; Medical Microbiology ; Mortality ; Original Article ; Patients ; Statistical analysis ; Success
  • É parte de: European journal of clinical microbiology & infectious diseases, 2022-09, Vol.41 (9), p.1173-1182
  • Notas: ObjectType-Article-1
    SourceType-Scholarly Journals-1
    ObjectType-Feature-2
    content type line 23
    ObjectType-Undefined-3
  • Descrição: Therapeutic options for bacteremia caused by carbapenem-resistant Enterobacterales (CRE) OXA-48-type are limited. The objective of this study was to analyze clinical success of CAZ-AVI compared with best available therapy (BAT) in patients with Klebsiella pneumoniae carbapenemase-producing OXA-48-type bacteremia (CRKp-OXA-48). We conducted a retrospective, single-center observational study in adult patients with CRKp-OXA-48 between December 2015 and May 2019. We collected the patients’ clinical and epidemiological characteristics, antibiotic treatment (CAZ-AVI vs. BAT), and evolution. Factors associated with clinical success were analyzed using binary logistic regression. The study included 76 patients with CRKp-OXA-48-type bacteremia 33 received CAZ-AVI and 43 BAT. CAZ-AVI was mainly used in monotherapy (91%). Clinical success was more common in patients < 70-year-old (OR 4.79, 95% CI [1.435–16.002], p  = 0.011) and CAZ-AVI treatment (OR 6.69, 95% CI [1.68–26.604], p  = 0.007). Kaplan–Meier survival curve of 14-day mortality showed a lower mortality in patients who received CAZ-AVI (log rank 0.013). However, CAZ-AVI did not achieve statistical difference in IPTW for 14- and 30-day mortality (aOR 0.1, 95% CI [0.02–1.22], p  = 0.076 and aOR 1.7, 95% CI [0.48–5.98], p  = 0.413, respectively). CAZ-AVI treatment might be associated with a greater clinical success in CRKp-OXA-48 bacteremia.
  • Editor: Berlin/Heidelberg: Springer Berlin Heidelberg
  • Idioma: Inglês
Voltar para lista de resultados
Ir para página anteriorAnterior Resultado  3 AvançarIr para próxima página

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.